Novo Nordisk

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. 

CEO
Lars Fruergaard Jørgensen
CEOLars Fruergaard Jørgensen
Employees
76,302
Employees76,302
Headquarters
Bagsværd, Capital Region
HeadquartersBagsværd, Capital Region
Founded
1931
Founded1931
Employees
76,302
Employees76,302

NVO Key Statistics

Market cap
346.85B
Market cap346.85B
Price-Earnings ratio
23.46
Price-Earnings ratio23.46
Dividend yield
1.33%
Dividend yield1.33%
Average volume
7.44M
Average volume7.44M
High today
$77.55
High today$77.55
Low today
$75.24
Low today$75.24
Open price
$75.75
Open price$75.75
Volume
6.51M
Volume6.51M
52 Week high
$148.15
52 Week high$148.15
52 Week low
$73.80
52 Week low$73.80

NVO News

Sherwood News 2d
Is Ozempic old news?

The race to create the next miracle weight-loss drug is ramping up. Here’s where things stand. Ozempic, a drug developed by Novo Nordisk to treat type 2 diabet...

Is Ozempic old news?
Quartz 2d
An Ozempic successor falls short, Eli Lilly's GLP-1 pill, and senators grill RFK: Pharma news roundup

An Eli Lilly exec said the company’s experimental weight-loss pill could make GLP-1 treatments more accessible worldwide, as it would be easier to manufacture a...

TipRanks 3d
Why This Long-Time Skeptic Finally Upgraded Novo Nordisk to Buy

Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after long-time skeptic Kepler...

Analyst ratings

69%

of 35 ratings
Buy
68.6%
Hold
28.6%
Sell
2.9%

More NVO News

TipRanks 3d
Novo Nordisk put volume heavy and directionally bearish

Bearish flow noted in Novo Nordisk (NVO) with 7,917 puts trading, or 1.2x expected. Most active are 3/14 weekly 76 puts and Sep-25 110 puts, with total volume i...

Sherwood News 4d
Hims & Hers threw a Super Bowl Hail Mary that landed incomplete. Now the receiver is on the sidelines.

Hims & Hers did get increased attention from the ad, but the product it showcased for millions of people is no longer at the center of its business model. Hims...

Hims & Hers threw a Super Bowl Hail Mary that landed incomplete. Now the receiver is on the sidelines.
Benzinga 5d
Novo Nordisk's Combo Drug CagriSema Shows 16% Weight Reduction In Second Phase 3 Trial

On Monday, Novo Nordisk A/S NVO announced headline results from the REDEFINE 2 phase 3 trial in the global REDEFINE program. REDEFINE 2 is a 68-week efficacy a...

Novo Nordisk's Combo Drug CagriSema Shows 16% Weight Reduction In Second Phase 3 Trial
TipRanks 6d
Novo Nordisk Sinks after Weight-Loss Drug Trial Misses Expectations

Shares of Novo Nordisk’s (NVO) are down over 9% at the time of writing after the company announced the results from its latest weight-loss drug trial, Redefine...

Quartz 6d
Novo Nordisk's Ozempic successor disappointed Wall Street, again

Novo Nordisk (NVO) released clinical trial results for its potential Ozempic successor on Monday, disappointing Wall Street for the second time. The pharmaceut...

Sherwood News 6d
Novo Nordisk dips after latest trial on its new weight-loss drug disappoints

Novo Nordisk dips after latest trial on its new weight-loss drug disappoints Novo Nordisk shares fell after the results for the latest trial of its next-genera...

Novo Nordisk dips after latest trial on its new weight-loss drug disappoints
TipRanks 6d
Morgan Stanley says REDEFINE-2 misses opportunity to differentiate in diabetes

Morgan Stanley notes Novo Nordisk (NVO) disclosed headline data for CagriSema in REDEFINE-2, with a weight loss and safety profile similar to Eli Lilly’s (LLY)...

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.